Cardiovascular Moderate to Severe Hereditary Dog

Mitral Valve Disease

Also known as: MVD, Myxomatous Mitral Valve Disease, MMVD, Endocardiosis

Myxomatous Mitral Valve Disease (MMVD) is the most common acquired heart disease in dogs, accounting for approximately 75% of all canine heart disease. The mitral valve leaflets undergo progressive myxomatous degeneration, becoming thickened and distorted, leading to valve incompetence (regurgitation) and eventually congestive heart failure.

Symptoms & Signs

Causes & Risk Factors

Progressive myxomatous degeneration of valve tissue with genetic predisposition. The valve leaflets accumulate glycosaminoglycans, becoming thickened, elongated, and incompetent. Small breeds are most commonly affected. Cavalier King Charles Spaniels have particularly early onset and high prevalence.

Diagnosis

Cardiac auscultation (left apical systolic murmur, graded I-VI). Echocardiography for staging (ACVIM stages A-D): valve morphology, chamber dimensions, regurgitation severity. Thoracic radiographs for heart size and pulmonary edema. NT-proBNP as biomarker.

Treatment

Stage B1 (murmur, no enlargement): monitoring. Stage B2 (enlargement): pimobendan to delay heart failure onset. Stage C (heart failure): pimobendan, furosemide, ACE inhibitor (benazepril/enalapril). Stage D (refractory): additional diuretics, sildenafil. Mitral valve repair surgery at specialized centers.

Prevention

Breeding programs with cardiac screening (echocardiography at age 5+ for Cavaliers). Avoiding breeding of dogs with early-onset murmurs. No proven dietary or lifestyle prevention.

Prognosis

Stage B1: many dogs live years without progression. Stage B2 with pimobendan: median 1300+ days to heart failure. Stage C with treatment: median survival 6-14 months. Stage D: weeks to months. Surgical repair can be curative.

Affected Breeds (2)

BreedSpeciesSize
Cavalier King Charles SpanielDogSmall
WhippetDogMedium

Related Conditions